The fastest path to breakthroughs and cures is through shared ambition, knowledge and investment, write three cancer experts at follicular lymphoma nonprofits.

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, ...

Semaglutide reduced liver fat and improved fibrosis in people with MASH—adding to the drug’s growing list of benefits—and several other GLP-1 meds look promising.

Nearly three quarters of non-small-cell lung cancer (NSCLC) patients with HER2 mutations experienced tumor regression when treated with zongertinib, a novel targeted therapy, according to results from ...

UCSF grad students present research about how to track down HIV, fight brain tumors with T cells and treat brain disorders prenatally. [VIDEO] ...

Pandemic Potential About 65 dairy and poultry workers have tested positive for the bird flu since March 2024, but the true number of infections is higher. A KFF Health News investigation found that ...

“You must go get your test,” urges Knowles, mom to Beyoncé and Solange. Docs could have found her cancer earlier, she says in her new memoir, “Matriarch.” ...

The American Association for Cancer Research (AACR) today announced the launch of the AACR Trailblazer Cancer Research Grant Program during the Opening Ceremony of the AACR Annual Meeting 2025. This ...

Automated templates on the Halo Intelligence platform will allow clinicians to rapidly identify the most effective treatment plan for each patient ...

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life. Acne-like skin rash is a common side effect from ...

Most people with mismatch repair deficient (dMMR) cancers who used the checkpoint inhibitor Jemperli (dostarlimab) were able to forgo surgery and maintain their quality of life, according to study ...

Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in ...